|
Time to COVID-19 RT-PCR clearance among patients with cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Pfizer; Takeda/Millennium |
Consulting or Advisory Role - AstraZeneca; Takeda/Millennium |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Merck (Inst); Merrimack (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst); Takeda/Millennium (Inst) |
|
Mary Linton Bounetheau Peters |
Stock and Other Ownership Interests - Abbott Laboratories (I); Amgen (I); Johnson & Johnson (I); Lilly; Lilly (I); Medtronic; Medtronic (I); Merck; Pfizer (I); Procter & Gamble |
Honoraria - Bayer; Exelixis |
Consulting or Advisory Role - Agios |
Research Funding - Ambry Genetics (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Berg Pharma (Inst); Exelixis (Inst); Merck (Inst); Taiho Pharmaceutical (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Exelixis; Halozyme |